A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors

NCT00455052 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer
Non-small Cell Lung Cancer

Interventions

DRUG: XMT-1001

Sponsor

Mersana Therapeutics